Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INC003
MIFTS: 45

Inclusion Conjunctivitis

Categories: Eye diseases, Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Inclusion Conjunctivitis

About this section

MalaCards integrated aliases for Inclusion Conjunctivitis:

Name: Inclusion Conjunctivitis 12 77 54 15 17 74
Inclusion Conjunctivitis of the Adult 74
Neonatal Chlamydial Conjunctivitis 74
Adult Inclusion Conjunctivitis 12
Chlamydial Conjunctivitis 12
Conjunctivitis, Inclusion 45
Inclusion Blennorrhoea 12
Inclusion Blenorrhea 12
Paratrachoma 12

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:13800
ICD9CM 36 077.0
MeSH 45 D003235
SNOMED-CT 69 56009001
ICD10 34 A74.0
Sources

Summaries for Inclusion Conjunctivitis

About this section
Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation, located in conjunctiva of the eye, has material basis in Chlamydia trachomatis, which is transmitted by sexual contact. The infection has symptom swollen conjunctiva and eyelids and has symptom discharge of pus and mucus.

MalaCards based summary : Inclusion Conjunctivitis, also known as inclusion conjunctivitis of the adult, is related to salpingitis and conjunctivitis, and has symptoms including swollen conjunctiva and discharge of pus. An important gene associated with Inclusion Conjunctivitis is WDR13 (WD Repeat Domain 13), and among its related pathways/superpathways are Lung fibrosis and EBV LMP1 signaling. The drugs Azithromycin and Permethrin have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and conjunctiva of the eye, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Inclusion Conjunctivitis

About this section

Diseases related to Inclusion Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 salpingitis 30.2 OVGP1 TNF
2 conjunctivitis 10.8
3 trachoma 10.6
4 chlamydia 10.4
5 acute conjunctivitis 10.4 PLD3 PSEN2
6 acute hemorrhagic conjunctivitis 10.4 PLD3 PSEN2
7 whiplash 10.3 CCL5 IL16
8 scorpion envenomation 10.3 CCL5 TNF
9 staphylococcal toxic shock syndrome 10.3 HMGB1 TNF
10 shipyard eye 10.3 PLD3 PSEN2
11 iritis 10.3 MRAP PSEN2
12 whipple disease 10.3 IL16 MRAP
13 respiratory syncytial virus infectious disease 10.3 CCL5 IL5
14 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL5 TNF
15 posterior scleritis 10.3 MRAP TNF
16 juvenile ankylosing spondylitis 10.2 MRAP TNF
17 scleritis 10.2 IL5 TNF
18 scleral disease 10.2 MRAP TNF
19 pustulosis of palm and sole 10.2 MRAP TNF
20 cerebral artery occlusion 10.2 IL16 TNF
21 macrophage activation syndrome 10.2 HMGB1 TNF
22 cow milk allergy 10.2 IL5 TNF
23 chronic conjunctivitis 10.2 CCL5 IL5
24 acute salpingitis 10.2 MRAP OVGP1 TNF
25 allergic asthma 10.2 CCL5 IL16 IL5
26 status asthmaticus 10.1 CCL5 IL5
27 diffuse infiltrative lymphocytosis syndrome 10.1 MRAP TNF
28 idiopathic neutropenia 10.1 CCL5 HMGB1 TNF
29 chronic eosinophilic pneumonia 10.1 CCL5 IL5
30 churg-strauss syndrome 10.1 HMGB1 IL5 TNF
31 filariasis 10.1 CCL5 IL5 TNF
32 upper respiratory tract disease 10.1 CCL5 IL5 TNF
33 bronchial disease 10.1 CCL5 IL5 TNF
34 bronchiolitis 10.1 CCL5 IL5 TNF
35 proteasome-associated autoinflammatory syndrome 1 10.1 CCL5 IL5 TNF
36 respiratory system disease 10.1 CCL5 IL5 TNF
37 urethritis 10.1
38 stachybotrys chartarum 10.1 CCL5 TNF
39 endophthalmitis 10.0 HMGB1 MRAP
40 lymphogranuloma venereum 10.0
41 pneumonia 10.0 CCL5 IL5 TNF
42 dermatitis, atopic 10.0 CCL5 IL16 IL5 TNF
43 otitis media 10.0
44 arthritis 10.0
45 uveitis 10.0
46 cellulitis 10.0
47 reactive arthritis 10.0
48 ornithosis 10.0
49 kimura disease 9.9 CCL5 IL5
50 conjunctival disease 9.8 IL5 MRAP PLD3 PSEN2 TNF

Graphical network of the top 20 diseases related to Inclusion Conjunctivitis:



Diseases related to Inclusion Conjunctivitis
Sources

Symptoms & Phenotypes for Inclusion Conjunctivitis

About this section

Symptoms:

12
  • • swollen conjunctiva
  • • discharge of pus

GenomeRNAi Phenotypes related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

27 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.53 PSEN2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.53 CWC15
3 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.53 PSEN2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.53 HMGB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.53 PSEN2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.53 HMGB1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.53 CWC15
8 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.53 CWC15
9 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.53 CWC15
10 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.53 CWC15
11 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.53 CWC15 HMGB1 PSEN2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-69 9.53 HMGB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.53 PSEN2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.53 HMGB1
Sources

Drugs & Therapeutics for Inclusion Conjunctivitis

About this section

Drugs for Inclusion Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 447043 55185
2
Permethrin Approved, Investigational Phase 4,Phase 2 52645-53-1 40326
3
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
4
Albendazole Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54965-21-8 2082
5
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 70288-86-7 6474909
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Sulfamethoxazole Approved Phase 4 723-46-6 5329
8
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
9 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Anti-Infective Agents Phase 4,Phase 3,Not Applicable
12 Anthelmintics Phase 4,Phase 3,Not Applicable
13 Antimitotic Agents Phase 4,Phase 3,Not Applicable
14 Antiparasitic Agents Phase 4,Phase 3,Not Applicable
15 Antiprotozoal Agents Phase 4,Phase 3,Not Applicable
16 Antitubercular Agents Phase 4
17 Antimalarials Phase 4
18 Anti-Infective Agents, Urinary Phase 4
19 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
20 Renal Agents Phase 4
21 Immunologic Factors Phase 4,Phase 1
22 Vaccines Phase 4,Phase 1
23
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
24 Ophthalmic Solutions Phase 3,Not Applicable
25 Pharmaceutical Solutions Phase 3,Not Applicable
26 Lipoxygenase Inhibitors Phase 3
27 Insect Repellents Phase 2
28 Protective Agents Phase 2
29
Fluorometholone Approved, Investigational Not Applicable 426-13-1 9878
30
Formaldehyde Approved, Vet_approved Not Applicable 50-00-0 712
31 Lubricant Eye Drops Not Applicable
32 Hormone Antagonists Not Applicable
33 Anti-Inflammatory Agents Not Applicable
34 Anti-Allergic Agents Not Applicable
35 glucocorticoids Not Applicable
36 Hormones Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Partnership for Rapid Elimination of Trachoma Completed NCT00792922 Phase 4 Azithromycin;Azithromycin
2 Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Completed NCT00347763 Phase 4
3 Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania Completed NCT00347607 Phase 4
4 Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
5 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4 Azithromcyin;Azithromycin
6 Trachoma Elimination Follow-up Completed NCT00221364 Phase 4 Mass treatment with oral azithromycin to an entire village
7 Trachoma Amelioration in Northern Amhara (TANA) Completed NCT00322972 Phase 4 Mass treatment with oral azithromycin to an entire community
8 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
9 A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Completed NCT00522860 Phase 4
10 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia Completed NCT00347776 Phase 4 azithromycin;topical tetracycline
11 Mortality Reduction After Oral Azithromycin: Mortality Study Completed NCT02047981 Phase 4 Azithromycin;Placebo
12 Sanitation, Water, and Instruction in Face-washing for Trachoma Recruiting NCT02754583 Phase 4 Azithromycin;Tetracycline;Albendazole
13 Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children Recruiting NCT02414399 Phase 4 Azithromycin;Placebo
14 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso Active, not recruiting NCT03187834 Phase 4 Azithromycin;Amoxicillin;Cotrimoxazole;Placebo
15 Mortality Reduction After Oral Azithromycin: Morbidity Study Enrolling by invitation NCT02048007 Phase 4 Azithromycin;Placebo
16 Trachoma Elimination Study by Focused Antibiotic (TESFA) Not yet recruiting NCT03523156 Phase 4 Azithromycin mass treatment;Azithromycin targeted treatment
17 Kebele Elimination of Trachoma for Ocular Health Not yet recruiting NCT03335072 Phase 4 Azithromycin
18 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
19 Community Health Azithromycin Trial in Burkina Faso Not yet recruiting NCT03676764 Phase 4 Azithromycin;Placebos
20 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4 Azithromycin
21 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
22 Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Completed NCT00356720 Phase 3 Azithromycin
23 Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
24 Prevention of Bacterial Infections in Newborn Completed NCT01800942 Phase 3 Azithromycin and Placebo
25 Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death Recruiting NCT03199547 Phase 3 Azithromycin;Placebo Oral Tablet
26 Nepal Elimination of Trachoma Study Withdrawn NCT02176057 Phase 2, Phase 3 Azithromycin
27 Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Suspended NCT03813069 Phase 2
28 Safety and Immunogenicity of a Chlamydia Vaccine CTH522 Not yet recruiting NCT03926728 Phase 1
29 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Completed NCT01178762 Not Applicable Azithromycin
30 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Completed NCT01767506 Not Applicable
31 Modified Instrumentation for Surgery to Correct Trichiasis Completed NCT00886015 Not Applicable
32 Water Uptake for Health in Amhara Pilot Completed NCT02373657 Not Applicable
33 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 Not Applicable triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
34 Identification of TT Cases by Community Treatment Assistants: An Assessment Completed NCT01783743 Not Applicable
35 Fluorometholone as Ancillary Therapy for TT Surgery Completed NCT01949454 Not Applicable Fluorometholone 0.1% ophthalmic solution
36 The Effect of Long-Term HEAD START Training on Surgical Skill Levels Completed NCT03135080 Not Applicable
37 A Trial of Epilation Verses Surgery for Minor Trichiasis Completed NCT00522912 Not Applicable
38 Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze Completed NCT00439114
39 Histology Evaluation of Radiofrequency Ablation Not yet recruiting NCT03947723 Not Applicable
40 Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Withdrawn NCT02655432

Search NIH Clinical Center for Inclusion Conjunctivitis

Cochrane evidence based reviews: conjunctivitis, inclusion

Sources

Genetic Tests for Inclusion Conjunctivitis

About this section
Sources

Anatomical Context for Inclusion Conjunctivitis

About this section

MalaCards organs/tissues related to Inclusion Conjunctivitis:

42
Eye, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Inclusion Conjunctivitis:

20
Conjunctiva Of The Eye
Sources

Publications for Inclusion Conjunctivitis

About this section

Articles related to Inclusion Conjunctivitis:

(show top 50) (show all 111)
# Title Authors Year
1
Conjunctival infection with Chlamydia trachomatis in sexual partners of patients with adult inclusion conjunctivitis. ( 24643518 )
2015
2
Evaluation of single-dose azithromycin versus standard azithromycin/doxycycline treatment and clinical assessment of regression course in patients with adult inclusion conjunctivitis. ( 24047438 )
2013
3
Evaluation of direct immunofluorescence assay and cytological examination in comparison to polymerase chain reaction of conjunctival swabs in patients with adult inclusion conjunctivitis. ( 23627371 )
2013
4
Effect of inflammatory response on in vivo competition between two chlamydial variants in the guinea pig model of inclusion conjunctivitis. ( 22144478 )
2012
5
Combination of adult inclusion conjunctivitis and mucosa-associated lymphoid tissue (MALT) lymphoma in a young adult. ( 14701961 )
2004
6
Azithromycin vs doxycycline in the treatment of inclusion conjunctivitis. ( 12654359 )
2003
7
Phage infection of the obligate intracellular bacterium, Chlamydia psittaci strain guinea pig inclusion conjunctivitis. ( 10955956 )
2000
8
Microvirus of chlamydia psittaci strain guinea pig inclusion conjunctivitis: isolation and molecular characterization. ( 10878129 )
2000
9
Serotyping of Chlamydia trachomatis from inclusion conjunctivitis by polymerase chain reaction and restriction fragment length polymorphism analysis. ( 8876399 )
1996
10
Homologs of Escherichia coli recJ, gltX and of a putative 'early' gene of avian Chlamydia psittaci are located upstream of the 'late' omp2 locus of Chlamydia psittaci strain guinea pig inclusion conjunctivitis. ( 8918248 )
1996
11
Immunity to reinfection and immunization of male guinea pigs against urethral infection with the agent of guinea pig inclusion conjunctivitis. ( 8919742 )
1996
12
Increased incidence of oviduct pathology in the guinea pig after repeat vaginal inoculation with the chlamydial agent of guinea pig inclusion conjunctivitis. ( 7709325 )
1995
13
Evaluation of the Kodak Surecell Chlamydia test for the laboratory diagnosis of adult inclusion conjunctivitis. ( 9121749 )
1995
14
Diagnosing inclusion conjunctivitis. ( 7852700 )
1994
15
Dissociation of immune determinants of outer membrane proteins of Chlamydia psittaci strain guinea pig inclusion conjunctivitis. ( 7525489 )
1994
16
Lack of allelic polymorphism for the major outer membrane protein gene of the agent of guinea pig inclusion conjunctivitis (Chlamydia psittaci). ( 8514416 )
1993
17
Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. ( 7510322 )
1993
18
Monoclonal antibodies to Chlamydia psittaci guinea pig inclusion conjunctivitis (GPIC) strain. ( 2186565 )
1990
19
Guineapig inclusion conjunctivitis (GPIC) in a commercial colony. ( 2651796 )
1989
20
Role of cell-mediated immunity in the resolution of secondary chlamydial genital infection in guinea pigs infected with the agent of guinea pig inclusion conjunctivitis. ( 2917782 )
1989
21
Ultrastructural studies on the intracellular fate of Chlamydia psittaci (strain guinea pig inclusion conjunctivitis) and Chlamydia trachomatis (strain lymphogranuloma venereum 434): modulation of intracellular events and relationship with endocytic mechanism. ( 2614396 )
1989
22
Persistence of inclusion conjunctivitis after oral erythromycin therapy. ( 3179892 )
1988
23
Regulation of Chlamydia psittaci (strain guinea pig inclusion conjunctivitis) growth in McCoy cells by amino acid antagonism. ( 3655729 )
1987
24
Electron microscopic observations concerning the in vivo uptake and release of the agent of guinea-pig inclusion conjunctivitis (Chlamydia psittaci) in guinea-pig exocervix. ( 4031129 )
1985
25
Chlamydial inclusion conjunctivitis of the newborn. ( 6834172 )
1983
26
Differential amino acid utilization by Chlamydia psittaci (strain guinea pig inclusion conjunctivitis) and its regulatory effect on chlamydial growth. ( 6415225 )
1983
27
A study of inclusion conjunctivitis in newborn and young adults. Clinical picture, culture, conjunctival scrapings and cytology of the tear fluid in 12 cases. ( 6362323 )
1983
28
'Innocent' neonatal inclusion conjunctivitis: parental origins and complications. ( 21289694 )
1981
29
Ocular and dermal delayed hypersensitivity reactions in guinea-pigs following infection with guinea-pig inclusion conjunctivitis agent (Chlamydia psittaci). ( 7261478 )
1981
30
Adult inclusion conjunctivitis. Clinical characteristics and corneal changes. ( 7224930 )
1981
31
Serum and tear antibodies to Chlamydia after reinfection with guinea pig inclusion conjunctivitis agent. ( 7031009 )
1981
32
Cell-mediated and humoral immune responses to chlamydial antigens in guinea pigs infected ocularly with the agent of guinea pig inclusion conjunctivitis. ( 7012031 )
1981
33
Guinea-pig inclusion conjunctivitis as a model for the study of trachoma: clinical, microbiological, serological, and cytological studies of primary infection. ( 7387961 )
1980
34
Humoral immunity in the resolution of genital infection in female guinea pigs infected with the agent of guinea pig inclusion conjunctivitis. ( 546788 )
1979
35
Experimental chlamydial salpingitis in immunosuppressed guinea pigs infected in the genital tract with the agent of guinea pig inclusion conjunctivitis. ( 397933 )
1979
36
Target tissues associated with genital infection of female guinea pigs by the chlamydial agent of guinea pig inclusion conjunctivitis. ( 374637 )
1979
37
Immunity to vaginal reinfection in female guinea pigs infected sexually with Chlamydia of guinea pig inclusion conjunctivitis. ( 640729 )
1978
38
Staphylococcal infection superimposed on guinea pig inclusion conjunctivitis. ( 638844 )
1978
39
Severe persistent inclusion conjunctivitis in a young child. ( 848548 )
1977
40
Limited survey of genital infection by guinea pig inclusion conjunctivitis agent. ( 921034 )
1977
41
Resistance to reinfection with a chlamydial agent (guinea pig inclusion conjunctivitis agent). ( 863616 )
1977
42
The effect of cyclophosphamide on the recovery from a local chlamydial infection. Guinea-pig inclusion conjunctivitis (GPIC). ( 1088418 )
1976
43
Ultrastructural study of trachoma and inclusion conjunctivitis. ( 1028127 )
1976
44
Intrarectal infection of guinea pigs with the agent of guinea pig inclusion conjunctivitis. ( 1013148 )
1976
45
Infectivity titration of guinea-pig inclusion conjunctivitis agent in irradiated McCoy cells. ( 986419 )
1976
46
Animal model studies of genital chlamydial infections. Immunity to re-infection with guinea-pig inclusion conjunctivitis agent in the urethra and eye of male guinea-pigs. ( 963491 )
1976
47
A simplified method for immunological typing of trachoma-inclusion conjunctivitis-lymphogranuloma venereum organisms. ( 16558075 )
1973
48
Three new immunologic types of trachoma-inclusion conjunctivitis organisms. ( 4631875 )
1973
49
Experimental genital infection of male guinea pigs with the agent of guinea pig inclusion conjunctivitis and transmission to females. ( 4594119 )
1973
50
Immunity to chlamydial infections of the eye. II. Studies of passively transferred serum antibody in resistance to infection with guinea pig inclusion conjunctivitis. ( 4586860 )
1973
Sources

Variations for Inclusion Conjunctivitis

About this section
Sources

Expression for Inclusion Conjunctivitis

About this section
Search GEO for disease gene expression data for Inclusion Conjunctivitis.
Sources

Pathways for Inclusion Conjunctivitis

About this section

Pathways related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Lung fibrosis 1
10.93 CCL5 IL5 TNF
2
EBV LMP1 signaling 1
10.54 CCL5 TNF
3
G-protein signaling_RhoB regulation pathway 23
10.15 CCL5 IL16 IL5 TNF
Sources

GO Terms for Inclusion Conjunctivitis

About this section

Cellular components related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 ANXA5 CCL5 HMGB1 IL16 IL5 OVGP1

Biological processes related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.67 CCL5 HMGB1 IL5 TNF
2 positive regulation of JAK-STAT cascade GO:0046427 9.43 CCL5 IL5
3 positive regulation of innate immune response GO:0045089 9.4 CCL5 HMGB1
4 cytokine-mediated signaling pathway GO:0019221 9.35 CCL5 IL16 IL5 TNF TXLNA
5 positive regulation of monocyte chemotaxis GO:0090026 9.32 CCL5 HMGB1
6 dendritic cell chemotaxis GO:0002407 9.26 CCL5 HMGB1
7 positive regulation of podosome assembly GO:0071803 9.16 IL5 TNF
8 regulation of signaling receptor activity GO:0010469 9.1 CCL5 HMGB1 IL16 IL5 TNF TXLNA

Molecular functions related to Inclusion Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL5 HMGB1 IL16 IL5 TNF TXLNA
Sources

Sources for Inclusion Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....